113 related articles for article (PubMed ID: 37397990)
1. MCAK Inhibitors Induce Aneuploidy in Triple Negative Breast Cancer Models.
Smith JC; Husted S; Pilrose J; Ems-McClung SC; Stout JR; Carpenter RL; Walczak CE
bioRxiv; 2023 Jun; ():. PubMed ID: 37397990
[TBL] [Abstract][Full Text] [Related]
2. MCAK Inhibitors Induce Aneuploidy in Triple-Negative Breast Cancer Models.
Smith JC; Husted S; Pilrose J; Ems-McClung SC; Stout JR; Carpenter RL; Walczak CE
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444419
[TBL] [Abstract][Full Text] [Related]
3. An Orally Available Tubulin Inhibitor, VERU-111, Suppresses Triple-Negative Breast Cancer Tumor Growth and Metastasis and Bypasses Taxane Resistance.
Deng S; Krutilina RI; Wang Q; Lin Z; Parke DN; Playa HC; Chen H; Miller DD; Seagroves TN; Li W
Mol Cancer Ther; 2020 Feb; 19(2):348-363. PubMed ID: 31645441
[TBL] [Abstract][Full Text] [Related]
4. GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer.
Vijay GV; Zhao N; Den Hollander P; Toneff MJ; Joseph R; Pietila M; Taube JH; Sarkar TR; Ramirez-Pena E; Werden SJ; Shariati M; Gao R; Sobieski M; Stephan CC; Sphyris N; Miura N; Davies P; Chang JT; Soundararajan R; Rosen JM; Mani SA
Breast Cancer Res; 2019 Mar; 21(1):37. PubMed ID: 30845991
[TBL] [Abstract][Full Text] [Related]
5. SYTL4 downregulates microtubule stability and confers paclitaxel resistance in triple-negative breast cancer.
Liu XY; Jiang W; Ma D; Ge LP; Yang YS; Gou ZC; Xu XE; Shao ZM; Jiang YZ
Theranostics; 2020; 10(24):10940-10956. PubMed ID: 33042263
[No Abstract] [Full Text] [Related]
6. Effects of anti-microtubule agents on microtubule organization in cells lacking the kinesin-13 MCAK.
Hedrick DG; Stout JR; Walczak CE
Cell Cycle; 2008 Jul; 7(14):2146-56. PubMed ID: 18635958
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of autophagy by chloroquine prevents resistance to PI3K/AKT inhibitors and potentiates their antitumor effect in combination with paclitaxel in triple negative breast cancer models.
Cocco S; Leone A; Roca MS; Lombardi R; Piezzo M; Caputo R; Ciardiello C; Costantini S; Bruzzese F; Sisalli MJ; Budillon A; De Laurentiis M
J Transl Med; 2022 Jun; 20(1):290. PubMed ID: 35761360
[TBL] [Abstract][Full Text] [Related]
8. Targeting of apoptotic pathways by SMAC or BH3 mimetics distinctly sensitizes paclitaxel-resistant triple negative breast cancer cells.
Panayotopoulou EG; Müller AK; Börries M; Busch H; Hu G; Lev S
Oncotarget; 2017 Jul; 8(28):45088-45104. PubMed ID: 28187446
[TBL] [Abstract][Full Text] [Related]
9. Identification of new microtubule small-molecule inhibitors and microtubule-associated genes against triple negative breast cancer.
Chen J; Lin Z; Fan J; Monzavi-Karbassi B; Kelly T; Post SR; Dai L; Qin Z
Am J Cancer Res; 2024; 14(4):1545-1560. PubMed ID: 38726264
[TBL] [Abstract][Full Text] [Related]
10. Chromosomal and cytoplasmic context determines predisposition to maternal age-related aneuploidy: brief overview and update on MCAK in mammalian oocytes.
Eichenlaub-Ritter U; Staubach N; Trapphoff T
Biochem Soc Trans; 2010 Dec; 38(6):1681-6. PubMed ID: 21118147
[TBL] [Abstract][Full Text] [Related]
11. LIN9 confers paclitaxel resistance in triple negative breast cancer cells by upregulating CCSAP.
Lai H; Wang R; Li S; Shi Q; Cai Z; Li Y; Liu Y
Sci China Life Sci; 2020 Mar; 63(3):419-428. PubMed ID: 31420851
[TBL] [Abstract][Full Text] [Related]
12. Mitotic centromere-associated kinesin (MCAK): a potential cancer drug target.
Sanhaji M; Friel CT; Wordeman L; Louwen F; Yuan J
Oncotarget; 2011 Dec; 2(12):935-47. PubMed ID: 22249213
[TBL] [Abstract][Full Text] [Related]
13. Platinum and Taxane Based Adjuvant and Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Narrative Review.
Tian H; Ma D; Tan X; Yan W; Wu X; He C; Zhong L; Zhang Y; Yu B; Zhang Y; Qi X
Front Pharmacol; 2021; 12():770663. PubMed ID: 34938186
[TBL] [Abstract][Full Text] [Related]
14. Identified the novel resistant biomarkers for taxane-based therapy for triple-negative breast cancer.
Chou CW; Huang YM; Chang YJ; Huang CY; Hung CS
Int J Med Sci; 2021; 18(12):2521-2531. PubMed ID: 34104083
[TBL] [Abstract][Full Text] [Related]
15. TOP1 inhibition induces bifurcated JNK/MYC signaling that dictates cancer cell sensitivity.
Liu Q; Chung S; Murata MM; Han B; Gao B; Zhang M; Lee TY; Chirshev E; Unternaehrer J; Tanaka H; Giuliano AE; Cui Y; Cui X
Int J Biol Sci; 2022; 18(10):4203-4218. PubMed ID: 35844787
[No Abstract] [Full Text] [Related]
16. The small G-protein RalA promotes progression and metastasis of triple-negative breast cancer.
Thies KA; Cole MW; Schafer RE; Spehar JM; Richardson DS; Steck SA; Das M; Lian AW; Ray A; Shakya R; Knoblaugh SE; Timmers CD; Ostrowski MC; Chakravarti A; Sizemore GM; Sizemore ST
Breast Cancer Res; 2021 Jun; 23(1):65. PubMed ID: 34118960
[TBL] [Abstract][Full Text] [Related]
17. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
[TBL] [Abstract][Full Text] [Related]
18. Protein Phosphatase 1 Subunit PPP1R14B Stabilizes STMN1 to Promote Progression and Paclitaxel Resistance in Triple-Negative Breast Cancer.
Liao L; Zhang YL; Deng L; Chen C; Ma XY; Andriani L; Yang SY; Hu SY; Zhang FL; Shao ZM; Li DQ
Cancer Res; 2023 Feb; 83(3):471-484. PubMed ID: 36484700
[TBL] [Abstract][Full Text] [Related]
19. DZ-2384 has a superior preclinical profile to taxanes for the treatment of triple-negative breast cancer and is synergistic with anti-CTLA-4 immunotherapy.
Bernier C; Soliman A; Gravel M; Dankner M; Savage P; Petrecca K; Park M; Siegel PM; Shore GC; Roulston A
Anticancer Drugs; 2018 Sep; 29(8):774-785. PubMed ID: 29878901
[TBL] [Abstract][Full Text] [Related]
20. A novel EGR-1 dependent mechanism for YB-1 modulation of paclitaxel response in a triple negative breast cancer cell line.
Lasham A; Mehta SY; Fitzgerald SJ; Woolley AG; Hearn JI; Hurley DG; Ruza I; Algie M; Shelling AN; Braithwaite AW; Print CG
Int J Cancer; 2016 Sep; 139(5):1157-70. PubMed ID: 27072400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
